{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:29:15Z","timestamp":1785569355639,"version":"3.56.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with hematologic malignancies who undergo immunosuppressive therapies such as chimeric antigen receptor T-cell (CAR-T) therapy are at high risk of prolonged SARS-CoV-2 infection due to impaired humoral immunity. Treatment options remain limited, with variable efficacy, in such settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We describe a 21-year-old man with Down syndrome and B-cell acute lymphoblastic leukemia complicated by B-cell aplasia following CD19-directed CAR-T therapy. The patient developed COVID-19 and experienced persistent symptomatic infection, with high viral load and prolonged reverse transcriptase\u2013polymerase chain reaction (RT-PCR) positivity for more than 7 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Despite multiple courses of remdesivir and extended weekly infusions of COVID-19 convalescent plasma (CCP), the patient remained viremic and intermittently symptomatic. Anti\u2013SARS-CoV-2 immunoglobulin G titers were detectable only toward the latter time frame of treatment, and passive antibody therapy with CCP was insufficient for viral clearance. Ultimately, compassionate use of monoclonal antibody (mAb) therapy (casirivimab and imdevimab) was granted. Following administration, the patient achieved viral clearance for the first time, with resolution of symptoms and persistently negative RT-PCR findings for 8 months of available follow-up thereafter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case illustrates the limitations of CCP in patients with prolonged SARS-CoV-2 infection and highlights the effectiveness of mAbs in achieving viral clearance in severely immunocompromised hosts. It supports targeted use of mAb therapy in select high-risk populations and reinforces the importance of specific passive immunotherapy strategies (when available) for the management of viremia in immunodeficient patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/labmed\/lmaf047","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:36:23Z","timestamp":1750750583000},"page":"813-818","source":"Crossref","is-referenced-by-count":1,"title":["Prolonged COVID-19 infection in a patient with B-cell acute lymphoblastic leukemia maintained on convalescent plasma until recovery with monoclonal antibodies"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-635X","authenticated-orcid":false,"given":"Gagan","family":"Mathur","sequence":"first","affiliation":[{"name":"University of California, Irvine , Orange , CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8348-4893","authenticated-orcid":false,"given":"Jesse","family":"Qiao","sequence":"additional","affiliation":[{"name":"University of California, Irvine , Orange , CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"2025112208223050500_CIT0001","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J."},{"key":"2025112208223050500_CIT0002","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/QCO.0000000000000841","article-title":"Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside","volume":"35","author":"Laracy","year":"2022","journal-title":"Curr Opin Infect Dis."},{"key":"2025112208223050500_CIT0003","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1053\/j.jrn.2021.05.002","article-title":"A formula for the estimation of 24-hour urinary creatinine excretion: a derivation and validation study","volume":"32","author":"Kimura","year":"2022","journal-title":"J Ren Nutr."},{"key":"2025112208223050500_CIT0004","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.3390\/vaccines10122145","article-title":"SARS-CoV-2: an updated review highlighting its evolution and treatments","volume":"10","author":"Zhang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2025112208223050500_CIT0005","doi-asserted-by":"publisher","first-page":"797589","DOI":"10.3389\/fimmu.2022.797589","article-title":"Neutralization of SARS-CoV-2 variants by mRNA and adenoviral vector vaccine-elicited antibodies","volume":"13","author":"Tada","year":"2022","journal-title":"Front Immunol."},{"key":"2025112208223050500_CIT0006","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12879-022-07560-7","article-title":"Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study","volume":"22","author":"Rojas","year":"2022","journal-title":"BMC Infect Dis."},{"key":"2025112208223050500_CIT0007","doi-asserted-by":"publisher","first-page":"e1285","DOI":"10.1002\/cti2.1285","article-title":"Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors","volume":"10","author":"Steenhuis","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"2025112208223050500_CIT0008","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4049\/jimmunol.2100727","article-title":"Persistence of T cell and antibody responses to SARS-CoV-2 up to 9 months after symptom onset","volume":"208","author":"Law","year":"2022","journal-title":"J Immunol."},{"key":"2025112208223050500_CIT0009","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jama.2020.10245","article-title":"Monoclonal antibodies for prevention and treatment of COVID-19","volume":"324","author":"Marovich","year":"2020","journal-title":"JAMA."},{"key":"2025112208223050500_CIT0010","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1172\/JCI140200","article-title":"Early safety indicators of COVID-19 convalescent plasma in 5000 patients","volume":"130","author":"Joyner","year":"2020","journal-title":"J Clin Invest."},{"key":"2025112208223050500_CIT0011","doi-asserted-by":"publisher","first-page":"102847","DOI":"10.1016\/j.transci.2020.102847","article-title":"The true historical origin of convalescent plasma therapy","volume":"59","author":"Marson","year":"2020","journal-title":"Transfus Apher Sci."},{"key":"2025112208223050500_CIT0012","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3390\/v15030765","article-title":"Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis on randomized controlled trials","volume":"15","author":"Filippatos","year":"2023","journal-title":"Viruses"},{"key":"2025112208223050500_CIT0013","doi-asserted-by":"publisher","first-page":"CD013600","DOI":"10.1002\/14651858.CD013600.pub5","article-title":"Convalescent plasma for people with COVID-19: a living systematic review","volume":"2","author":"Iannizzi","year":"2023","journal-title":"Cochrane Database Syst Rev."},{"key":"2025112208223050500_CIT0014","doi-asserted-by":"publisher","first-page":"427","DOI":"10.14423\/SMJ.0000000000001546","article-title":"Convalescent plasma therapy in late-state, severe COVID-19 infection","volume":"116","author":"Kumar","year":"2023","journal-title":"South Med J."},{"key":"2025112208223050500_CIT0015","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development: progress, remaining challenges and future innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann Med Surg (Lond)"},{"key":"2025112208223050500_CIT0016","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"2025112208223050500_CIT0017","article-title":"Monoclonal antibody therapy for high-risk coronavirus (COVID-19) patients with mild to moderate disease presentations","volume-title":"StatPearls","author":"Aleem","year":"2022"},{"key":"2025112208223050500_CIT0018","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12941-021-00491-2","article-title":"Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy","volume":"20","author":"Taha","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob."},{"key":"2025112208223050500_CIT0019","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/hon.2974","article-title":"Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients\u2014a Czech multicenter experience","volume":"40","author":"Weinbergerov\u00e1","year":"2022","journal-title":"Hematol Oncol."},{"key":"2025112208223050500_CIT0020","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/jpids\/piac124","article-title":"Monoclonal antibody use for coronavirus disease 2019 in pediatric patients: a multicenter retrospective study","volume":"12","author":"Sherman","year":"2023","journal-title":"J. Pediatric Infect. Dis. Soc.."},{"key":"2025112208223050500_CIT0021","doi-asserted-by":"publisher","first-page":"13596535241264694","DOI":"10.1177\/13596535241264694","article-title":"Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort","volume":"29","author":"Nichols","year":"2024","journal-title":"Antivir Ther."},{"key":"2025112208223050500_CIT0022","doi-asserted-by":"publisher","first-page":"245","DOI":"10.14423\/SMJ.0000000000001503","article-title":"Banning monoclonal antibody therapies for COVID-19 using in vitro data","volume":"116","author":"Zitek","year":"2023","journal-title":"South Med J."},{"key":"2025112208223050500_CIT0023","author":"Reuters","year":"2024"},{"key":"2025112208223050500_CIT0024","year":"2025"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/6\/813\/63855257\/lmaf047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/6\/813\/63855257\/lmaf047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T13:22:40Z","timestamp":1763817760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/56\/6\/813\/8213976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,7,26]]},"published-print":{"date-parts":[[2025,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmaf047","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,26]]}}}